| Literature DB >> 24569896 |
Michael A Colman1, Marta Varela, Jules C Hancox, Henggui Zhang, Oleg V Aslanidi.
Abstract
AIMS: Atrial fibrillation (AF), the commonest cardiac arrhythmia, has been strongly linked with arrhythmogenic sources near the pulmonary veins (PVs), but underlying mechanisms are not fully understood. We aim to study the generation and sustenance of wave sources in a model of the PV tissue. METHODS ANDEntities:
Keywords: Atrial arrhythmias; Computational modelling; Drug effects; Pulmonary veins; Re-entrant waves
Mesh:
Substances:
Year: 2014 PMID: 24569896 PMCID: PMC3934846 DOI: 10.1093/europace/eut349
Source DB: PubMed Journal: Europace ISSN: 1099-5129 Impact factor: 5.214
Electrical heterogeneity and remodelling in the PV-LA region
| APD (ms) | ||||||
|---|---|---|---|---|---|---|
| LA control | 8.0 (8.5) | 5.0 (5.8) | 9.0 (8.4) | 5.0 (5.3) | 10.0 | 185 (195) |
| PV control | 6.0 (5.9) | 3.5 (3.6) | 4.5 (5.6) | 9.0 (9.8) | 10.0 | 173 (175) |
| LA remodelled | 4.0 (3.4) | 10.0 (9.3) | 4.0 (3.6) | 5.0 (5.0) | 5.0 | 112 (125) |
| PV remodelled | 3.0 (2.6) | 7.0 (6.1) | 2.0 (2.8) | 9.0 (9.8) | 5.0 | 107 (130) |
Ion channel current densities and APDs for the PV and LA cell models under control and full remodelling conditions. Simulated values are in good agreement with the respective experimental values[12] shown in brackets. Note that the current density of IKur (step current) in control is the same as in the original paper by Ramirez et al.[26] The current density of IKur in remodelling conditions is halved as seen in human atrial cells.[10]
Drug effects on the APD of the PV and LA cell models in the ion channel remodelling case
| Control | Remodelling | Remodelling + | Remodelling + | Remodelling + amiodarone | |
|---|---|---|---|---|---|
| LA APD (ms) | 185 | 112 | 189 | 138 | 92 |
| PV APD (ms) | 173 | 107 | 163 | 111 | 89 |
| 12 | 5 | 26 | 27 | 3 |
Drug effect on the electrical heterogeneity between the PV and LA cells is also quantified as ΔAPD.
Vulnerability of the PV tissue to re-entry initiation (VWCB) and sustenance (VWR)a
| VWCB (ms) | VWR (ms) | WL (mm) | |
|---|---|---|---|
| Control (no remodelling) | 221–239 | – | 171 |
| Cell-to-cell coupling reduction only | 215–243 | – | 102 |
| Ion channel remodelling only | 105–115 | – | 81 |
| Full remodelling (ion channel + coupling) | 103–115 | 107–109 | 49 |
| Full remodelling, isotropic tissue | 103–110 | – | 49 |
| Full remodelling, homogeneous tissue | 103–111 | 103 | 49 |
| Full remodelling + | 111–128 | – | 53 |
| Full remodelling + | 145–167 | – | 68 |
| Full remodelling + amiodarone | 97–101 | – | 46 |
| Cell-to-cell coupling reduction + | 222–246 | – | 105 |
| Cell-to-cell coupling reduction + | 335–368 | – | 159 |
| Cell-to-cell coupling reduction + amiodarone | 167–183 | – | 79 |
aThe vulnerability windows are quantified under various conditions and under effects of various pharmacological agents. The wavelength is measured as WL = ERP × CV, where ERP corresponds to the lower bound of the VWCB.